Structure Therapeutics Secures $100M Upfront Payment in GLP-1 Patent Licensing Deal with Genentech/Roche
GPCR has more than doubled off its 52-week low of $13.22.
Summary
Structure Therapeutics' subsidiary secured a non-exclusive patent licensing agreement with Genentech and Roche, receiving a $100 million upfront payment and future royalties for a GLP-1 receptor agonist compound.
Key Events · M&A and Partnerships · GPCR
-
Material Licensing Agreement
Gasherbrum Bio, a wholly-owned subsidiary of Structure Therapeutics, entered into a non-exclusive, royalty-bearing license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (GNE).
-
Significant Upfront Payment
Genentech will pay Gasherbrum a one-time, non-refundable payment of $100 million within 30 days of the agreement's execution.
-
Future Royalty Potential
Genentech also agreed to pay Gasherbrum royalties at a low single-digit rate on net sales of GNE Products containing CT-996, a proprietary GNE compound.
-
Preserves Core Programs
The license covers patents for a class of oral GLP-1 receptor agonists different from aleniglipron and does not encumber Structure Therapeutics' ongoing development programs.
Analysis · GPCR · Life Sciences
Structure Therapeutics' subsidiary, Gasherbrum Bio, has entered into a significant licensing agreement with Genentech and F. Hoffmann-La Roche. This deal provides a substantial $100 million non-refundable upfront payment and potential future royalties, significantly bolstering the company's financial position. Crucially, the non-exclusive license covers a class of GLP-1 receptor agonists distinct from Structure Therapeutics' ongoing core programs, allowing them to monetize intellectual property without encumbering their primary pipeline assets. This transaction provides non-dilutive capital and validates a portion of their patent portfolio, enhancing their ability to fund future development.
At the time of this filing, GPCR was trading at $62.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $13.22 to $94.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.